OSE Immunotherapeutics - Encouraging safety data for OSE-127
OSE Immunotherapeutics has announced that the data from its earlier Phase I study for OSE-127/S95011, initially released in 2019, has been...
207 Views
OSE Immunotherapeutics - FDA support received for Tedopi Phase III trial
OSE has announced that it has received positive recommendations from its ‘type C’ meeting with the FDA for the planned confirmatory Phase III trial...
284 Views
OSE Immunotherapeutics - Introducing its fifth clinical asset
OSE Immunotherapeutics has announced the first patient dosing in a new trial, marking the introduction of the company’s fifth asset to clinical...
668 Views
OSE Immunotherapeutics - €10m funding secures runway to Q323
OSE Immunotherapeutics (OSE) has announced the receipt of €10m in financing from the European Investment Bank (EIB), which we estimate will secure...
675 Views
OSE Immunotherapeutics - OSE-127 encouraging preclinical data in ALL
OSE Immunotherapeutics (OSE) has reported positive preclinical efficacy data for its novel monoclonal antibody therapy OSE-127 in B- and T-cell...
684 Views